Providence Health & Services
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Providence Health & Services sits in the top decile of US sponsors by registered trial count (#307 of 15,742 sponsors by registered trial count).
Providence Health & Services: 69 sponsored US clinical trials, 5 recruiting.
Providence Health & Services sponsors 69 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 32 completed. 6 of these trials are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
Providence Health & Services ranks in the top decile of sponsors by registered trial count (#307 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 45 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
69 total, page 1 of 2
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
NCT06719362
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT06353997
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT06175000
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
NCT05913388
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
NCT04470024
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT05349890
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
NCT05249114
Clinical Outcomes and Patient Satisfaction With Use of the Amma System
NCT05508984
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
NCT05308901
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT04520711
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
NCT04938609
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04895761
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT04373031
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
NCT04061980
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT03650894
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
NCT03336606
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
NCT03247712
Ipilimumab for Head and Neck Cancer Patients
NCT02812524
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
NCT02688712
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT02734290
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
NCT02422381
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
NCT02306954
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
NCT01416831
CAN1012 in Pre-Malignant DCIS and LCIS
NCT07408856
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
NCT04796584
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
NCT04417699
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
NCT05200143
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
NCT04627675
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
NCT05081700
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
NCT04175834
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
NCT03705351
Melatonin in Patients With Multiple Sclerosis (MS).
NCT03498131
Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients
NCT03289364
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
NCT03157830
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
NCT02950259
Pathogen Detection and Community Acquired Pneumonia
NCT02880384
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
NCT02575404
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
NCT02559024
ACTH for Fatigue in Multiple Sclerosis Patients
NCT02315872
Anti-OX40 Antibody in Head and Neck Cancer Patients
NCT02274155
α-TEA in Advanced Cancer
NCT02192346
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
NCT02117362
Telemedicine Technology Demonstration Project for Heart Failure
NCT02115620
Immunoscore in Rectal Cancer
NCT02017509
Phase I Study of Safety and Immunogenicity of ADU-623
NCT01967758
Main Study: Switch Sub-study: Switch-jcv
NCT01970410
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
NCT01909492
Chemoimmunotherapy and Radiation in Pancreatic Cancer
NCT01903083
Vaginal Delivery Debrief Checklist to Improve Team Communication
NCT01822158
Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients
NCT01822171
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 17 |
| Phase 3 | 5 |
| Phase 4 | 1 |
What is open in the Providence Health & Services pipeline
5 recruiting of 69 indexed (7% open); 32 completed (46%).
Phase mix: 6 late (III/IV) vs 47 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Providence Health & Services: open-pipeline peers nationwide
Peers matched on 69 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Providence Health & Services sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 69 trials (± recruiting share)
- Mallinckrodt · 69 trials · 0% recruiting
- Texas Tech University · 69 trials · 17% recruiting
- University of Colorado, Boulder · 69 trials · 22% recruiting
- Procter and Gamble · 70 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Radicle Science · 7% recruiting · 55 trials
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
Related
What to do with this Providence Health & Services page
69 registered trials is a research-attention snapshot, not an endorsement of Providence Health & Services or any single study.
- 5 of Providence Health & Services's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Providence Health & Services studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Providence Health & Services pipeline card: 69 registered trials from official public datasets.Report a data error.